Show simple item record

dc.contributor.authorWatson, M
dc.contributor.authorBuck, G
dc.contributor.authorWheatley, K
dc.contributor.authorHomewood, JR
dc.contributor.authorGoldstone, AH
dc.contributor.authorRees, JKH
dc.contributor.authorBurnett, AK
dc.date.accessioned2018-09-13T08:39:28Z
dc.date.issued2004-05
dc.identifier7
dc.identifier.citationEUROPEAN JOURNAL OF CANCER, 2004, 40 pp. 971 - 978
dc.identifier.issn0959-8049
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2677
dc.identifier.doi10.1016/S0959-8049(03)00628-2
dc.description.abstractThe increasing success of intensive consolidation chemotherapy (CCT) as an alternative to bone marrow transplant (BMT) in acute myeloid leukaemia (AML) necessitates comparison of the impact on quality of life (QoL) of these two treatment modalities. Most QoL studies following BMT involve small patient numbers and provide ambivalent results. The present study examines QoL in a large number of patients 1 year from the end of treatment within the United Kingdom Medical Research Council (UK MRC) AML10 trial of BMT versus CCT. Allogeneic-BMT (Allo-BMT) was observed to have an adverse impact on most QoL dimensions compared with Autologous-BMT (A-BMT) and CCT. More patients receiving BMT had mouth dryness problems and worse sexual and social relationships, professional and leisure activities than CCT patients. QoL in A-BMT patients was less impacted than Allo-BMT. Intention-to-treat analysis showed similar results. These results indicate that a reconsideration of treatment strategies is warranted, and that further, good prospective studies are needed to evaluate more clearly the effects of these treatments in long-term survivors. (C) 2003 Elsevier Ltd. All rights reserved.
dc.format.extent971 - 978
dc.languageeng
dc.language.isoeng
dc.titleAdverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients: analysis of the UK Medical Research Council AML 10 Trial
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/S0959-8049(03)00628-2
rioxxterms.licenseref.startdate2004-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEUROPEAN JOURNAL OF CANCER
pubs.notesorcid-numbers: Buck, Georgina/0000-0001-5909-4265 unique-id: ISI:000221467400015
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Psychology Research Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Psychology Research Group
pubs.volume40
pubs.embargo.termsNot known
icr.researchteamPsychology Research Groupen_US
dc.contributor.icrauthorWatson, Maggieen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record